PRINCETON, N.J. — Sandoz Inc. has introduced bimatoprost ophthalmic solution 0.03%, an eyelash treatment, in the U.S. market.
The Novartis subsidiary said its bimatoprost ophthalmic product is a generic version of Latisse from Allergan.
A prescription medicine, bimatoprost ophthalmic solution 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness and darkness. Eyelash hypotrichosis is a condition involving an insufficient number of eyelashes.
Sandoz said it’s marketing bimatoprost in the same 0.03% strength as the branded product.
“The launch of bimatoprost is an important addition to our industry-leading portfolio of ophthalmic products,” stated Peter Goldschmidt, president of Sandoz. “By expanding our ophthalmic offerings, Sandoz will increase patients’ access to a comprehensive range of quality medicines at affordable prices.”
U.S. sales for Latisse totaled approximately $75 million for the 12 months through October, according to IMS Health data reported by Sandoz.
